Cargando…
Does Losartan reduce the severity of COVID-19 in hypertensive patients?
BACKGROUND: One of the global problems is to control the coronavirus epidemic, and the role of different medicines is still unknown to policymakers. This study was conducted to evaluate the effects of losartan on the mortality rate of COVID-19 in hypertensive patients. METHODS: The research sample o...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933856/ https://www.ncbi.nlm.nih.gov/pubmed/35305551 http://dx.doi.org/10.1186/s12872-022-02548-2 |
_version_ | 1784671747870556160 |
---|---|
author | Mirjalili, Mohammadreza Soodejani, Moslem Taheri Raadabadi, Mehdi Dehghani, Ali Salemi, Fateme |
author_facet | Mirjalili, Mohammadreza Soodejani, Moslem Taheri Raadabadi, Mehdi Dehghani, Ali Salemi, Fateme |
author_sort | Mirjalili, Mohammadreza |
collection | PubMed |
description | BACKGROUND: One of the global problems is to control the coronavirus epidemic, and the role of different medicines is still unknown to policymakers. This study was conducted to evaluate the effects of losartan on the mortality rate of COVID-19 in hypertensive patients. METHODS: The research sample of analytical study included 1458 patients presenting to COVID-19 diagnostic centers in Yazd that were examined in the first six months of 2020. Data were analyzed using descriptive statistics as well as chi-square, Fisher’s exact test, t test, and logistic regression. RESULTS: Of 1458 subjects that were studied, 280 were hypertensive of whom 179 tested positive for SARS-CoV-2 PCR. The results showed a lower chance of death by more than 5 times in hypertensive patients who used losartan (P = 0.003). Moreover, regarding the effect of losartan on the prevention of COVID-19 in hypertensive patients, it was found that this medicine played a protective role although this relationship was not statistically significant (P = 0.86). CONCLUSIONS: The results showed that losartan reduced the chance of mortality in hypertensive patients. It is recommended that the effect of losartan and other blood pressure medicines on COVID-19 patients be investigated in larger studies as well as laboratory investigations. |
format | Online Article Text |
id | pubmed-8933856 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-89338562022-03-21 Does Losartan reduce the severity of COVID-19 in hypertensive patients? Mirjalili, Mohammadreza Soodejani, Moslem Taheri Raadabadi, Mehdi Dehghani, Ali Salemi, Fateme BMC Cardiovasc Disord Research BACKGROUND: One of the global problems is to control the coronavirus epidemic, and the role of different medicines is still unknown to policymakers. This study was conducted to evaluate the effects of losartan on the mortality rate of COVID-19 in hypertensive patients. METHODS: The research sample of analytical study included 1458 patients presenting to COVID-19 diagnostic centers in Yazd that were examined in the first six months of 2020. Data were analyzed using descriptive statistics as well as chi-square, Fisher’s exact test, t test, and logistic regression. RESULTS: Of 1458 subjects that were studied, 280 were hypertensive of whom 179 tested positive for SARS-CoV-2 PCR. The results showed a lower chance of death by more than 5 times in hypertensive patients who used losartan (P = 0.003). Moreover, regarding the effect of losartan on the prevention of COVID-19 in hypertensive patients, it was found that this medicine played a protective role although this relationship was not statistically significant (P = 0.86). CONCLUSIONS: The results showed that losartan reduced the chance of mortality in hypertensive patients. It is recommended that the effect of losartan and other blood pressure medicines on COVID-19 patients be investigated in larger studies as well as laboratory investigations. BioMed Central 2022-03-19 /pmc/articles/PMC8933856/ /pubmed/35305551 http://dx.doi.org/10.1186/s12872-022-02548-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Mirjalili, Mohammadreza Soodejani, Moslem Taheri Raadabadi, Mehdi Dehghani, Ali Salemi, Fateme Does Losartan reduce the severity of COVID-19 in hypertensive patients? |
title | Does Losartan reduce the severity of COVID-19 in hypertensive patients? |
title_full | Does Losartan reduce the severity of COVID-19 in hypertensive patients? |
title_fullStr | Does Losartan reduce the severity of COVID-19 in hypertensive patients? |
title_full_unstemmed | Does Losartan reduce the severity of COVID-19 in hypertensive patients? |
title_short | Does Losartan reduce the severity of COVID-19 in hypertensive patients? |
title_sort | does losartan reduce the severity of covid-19 in hypertensive patients? |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933856/ https://www.ncbi.nlm.nih.gov/pubmed/35305551 http://dx.doi.org/10.1186/s12872-022-02548-2 |
work_keys_str_mv | AT mirjalilimohammadreza doeslosartanreducetheseverityofcovid19inhypertensivepatients AT soodejanimoslemtaheri doeslosartanreducetheseverityofcovid19inhypertensivepatients AT raadabadimehdi doeslosartanreducetheseverityofcovid19inhypertensivepatients AT dehghaniali doeslosartanreducetheseverityofcovid19inhypertensivepatients AT salemifateme doeslosartanreducetheseverityofcovid19inhypertensivepatients |